ASMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Assembly Biosciences Inc (ASMB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown significant revenue growth in the latest quarter, its declining net income and EPS, combined with the lack of strong trading signals or positive news catalysts, suggest a cautious approach. Additionally, the recent price drop of -7.15% and neutral RSI indicate no immediate buying opportunity.
The MACD is positive but contracting, indicating weakening bullish momentum. The RSI is neutral at 38.672, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 26.891, and resistance is at 30.405. The stock is currently trading near its support level, suggesting limited downside risk but no strong upward momentum.
Hedge funds have significantly increased their buying activity by 161.98% over the last quarter, indicating institutional interest. The company's revenue grew by 57.62% YoY in Q3 2025.
Net income decreased by -4.34% YoY, and EPS dropped significantly by -52.32% YoY. There is no recent news or significant insider trading activity. The stock dropped -7.15% in the last session, and no trading signals (AI Stock Picker or SwingMax) are present.
In Q3 2025, revenue increased by 57.62% YoY to $10,789,000. However, net income declined by -4.34% YoY to -$9,196,000, and EPS dropped by -52.32% YoY to -0.72. Gross margin remained stable at 100%.
No recent analyst ratings or price target changes are available for ASMB.
